Iptacopan in Paroxysmal Nocturnal Hemoglobinuria: Mechanisms, Clinical Efficacy, Safety, and Quality of Life Outcomes. A Narrative Review
DOI:
https://doi.org/10.12775/QS.2026.59.72721Keywords
paroxysmal nocturnal hemoglobinuria, iptacopan, complement factor B inhibitor, quality of lifeAbstract
Background. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disorder caused by a somatic PIGA mutation with loss of CD55 and CD59. Anti-C5 agents control intravascular hemolysis but leave extravascular hemolysis unaddressed, causing persistent anemia.
Aim of the study. To synthesize current evidence on iptacopan — the first oral complement factor B inhibitor approved for PNH — covering mechanism, pharmacokinetics, efficacy, safety, and quality of life.
Material and methods. A structured PubMed/MEDLINE search was performed for English-language publications from January 2010 to March 2026, including Phase 2 and Phase 3 trials, pharmacokinetic studies, real-world cohorts, and case reports.
Results. Iptacopan inhibits factor B, controlling intravascular and extravascular hemolysis. In APPLY-PNH, 82.3% of patients switching from anti-C5 therapy achieved sustained hemoglobin rise ≥2 g/dL without transfusion versus 0% of controls (P<0.001). In APPOINT-PNH, 92.2% met the primary endpoint and 97.6% achieved transfusion independence at week 24; outcomes were maintained at 48 weeks. Fatigue improved in 51–56% of patients. Breakthrough hemolysis occurred in 5–7%, without discontinuations.
Conclusions. Iptacopan is the first approved oral monotherapy targeting both hemolysis pathways in PNH. Phase 3 and real-world evidence confirm efficacy, tolerability, and quality of life benefit, while reducing treatment burden versus intravenous inhibitors.
Keywords: paroxysmal nocturnal hemoglobinuria; iptacopan; complement factor B inhibitor; quality of life
References
1. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3(1):17028. doi:10.1038/nrdp.2017.28
2. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804-2811. doi:10.1182/blood-2014-02-522128
3. Luzzatto L. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria. F1000Res. 2016;5:F1000 Faculty Rev-209. doi:10.12688/f1000research.7288.1
4. Fattizzo B, Cavallaro F, Oliva EN, Barcellini W. Managing fatigue in patients with paroxysmal nocturnal hemoglobinuria. J Blood Med. 2022;13:327-335. doi:10.2147/JBM.S339660
5. de Castro CM, Patel BJ. Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Pharmacother. 2024;25(18):2331-2339. doi:10.1080/14656566.2024.2404110
6. Lee JW, Brodsky RA, Nishimura JI, Kulasekararaj AG. Current and emerging treatments for paroxysmal nocturnal hemoglobinuria. Expert Rev Clin Pharmacol. 2022;15(7):851-861. doi:10.1080/17512433.2022.2109462
7. Syed YY. Iptacopan: First Approval. Drugs. 2024;84(5):599-606. doi:10.1007/s40265-024-02009-4
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-797. doi:10.1038/ni.1923
9. Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? Front Immunol. 2019;10:1157. doi:10.3389/fimmu.2019.01157
10. Slesicka I, Przestrzelska M, Zozula N, et al. Chronic fatigue syndrome: insights and treatment perspectives — a literature review. Qual Sport. 2024;18:53589. doi:10.12775/QS.2024.18.53589
11. Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926-7931. doi:10.1073/pnas.1820892116
12. Risitano AM, Frieri C, Urciuoli E, Marano L. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: from a pathogenic mechanism to a therapeutic target. Immunol Rev. 2023;313(1):262-278. doi:10.1111/imr.13137
13. Muri L, Ispasanie E, Schubart A, et al. Alternative complement pathway inhibition abrogates pneumococcal opsonophagocytosis in vaccine-naive but not vaccinated individuals. Front Immunol. 2021;12:732146. doi:10.3389/fimmu.2021.732146
14. Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with PNH and active haemolysis: phase 2 proof-of-concept trial. Lancet Haematol. 2021;8(5):e344-e354. doi:10.1016/S2352-3026(21)00028-4
15. James AD, Kulmatycki K, Poller B, et al. Absorption, distribution, metabolism, and excretion of [¹⁴C]iptacopan in healthy male volunteers. Drug Metab Dispos. 2023;51(7):873-883. doi:10.1124/dmd.123.001290
16. Burmeister Getz E, Stein RR, Fink M, et al. Effect of target-mediated disposition on iptacopan clinical pharmacokinetics in participants with normal or impaired hepatic function. Clin Pharmacol Ther. 2025;117(5):1358-1368. doi:10.1002/cpt.3559
17. Wu T, Wang XQ. Iptacopan in a paroxysmal nocturnal hemoglobinuria patient with severe renal insufficiency [case report]. Front Med (Lausanne). 2025;12:1583394. doi:10.3389/fmed.2025.1583394
18. Jang JH, Wong L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450-4460. doi:10.1182/bloodadvances.2022006960
19. Peffault de Latour R, Röth A, Kulasekararaj AG, et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2024;390(11):994-1008. doi:10.1056/NEJMoa2308695
20. Risitano AM, Kulasekararaj A, Röth A, et al. Oral iptacopan monotherapy in PNH: final 48-week results from APPLY-PNH and APPOINT-PNH. Lancet Haematol. 2025;12(6):e414-e430. doi:10.1016/S2352-3026(25)00081-X
21. Risitano AM, de Castro C, Han B, et al. Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies. Blood Adv. 2025;9(8):1816-1826. doi:10.1182/bloodadvances.2024014652
22. DeCastro C, Scheinberg P, Han B, et al. Patient-reported meaningful change in symptoms and impacts of paroxysmal nocturnal hemoglobinuria (PNH) in three phase III clinical trials of iptacopan. Patient. 2025;18(6):699-712. doi:10.1007/s40271-025-00755-5
23. Kelly RJ, Kulasekararaj AG, Arnold LM, et al. Oral iptacopan for paroxysmal nocturnal haemoglobinuria — first real-world experience. Br J Haematol. 2025;206(4):1241-1245. doi:10.1111/bjh.20024
24. Holt M, Kelly RJ, Fermont JM, et al. Effectiveness of iptacopan versus C5 inhibitors in complement inhibitor-naive patients with paroxysmal nocturnal haemoglobinuria. eJHaem. 2025;6(3):e270055. doi:10.1002/jha2.70055
25. Füreder W, Thalhammer R, Valent P. Resolution of extravascular hemolysis with oral iptacopan monotherapy in treatment-experienced PNH. Wien Klin Wochenschr. 2024;136(15-16):472-475. doi:10.1007/s00508-024-02390-w
26. Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392(6):531-543. doi:10.1056/NEJMoa2410316
27. Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled phase 2 study proposing iptacopan as a complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024;105(1):189-199. doi:10.1016/j.kint.2023.09.027
28. Kavanagh D, Bomback AS, Vivarelli M, et al. Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, phase 3 study. Lancet. 2025;406(10512):1587-1598. doi:10.1016/S0140-6736(25)01148-1
29. Wong E, Nester C, Cavero T, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy. Kidney Int Rep. 2023;8(12):2754-2764. doi:10.1016/j.ekir.2023.09.017
30. Bomback AS, Kavanagh D, Vivarelli M, et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy — study design of the APPEAR-C3G trial. Kidney Int Rep. 2022;7(10):2150-2159. doi:10.1016/j.ekir.2022.07.004
31. Szwech J, Matczak M, Jasiński K, et al. Clinical presentation and treatment of thrombotic thrombocytopenic purpura — analysis of recent diagnostic and therapeutic methods. J Educ Health Sport. 2025;79:57872. doi:10.12775/JEHS.2025.79.57872
32. Kulasekararaj A, Sicre de Fontbrune F, Gaya A, et al. APPULSE-PNH: oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria and hemoglobin ≥10 g/dL on anti-C5 therapy. Abstract S183 presented at: European Hematology Association 2025 Congress; June 12–15, 2025; Milan, Italy.
33. de Latour RP, Kulasekararaj A, Dingli D, et al. Anchored indirect treatment comparison finds comparable effects of pegcetacoplan and iptacopan in paroxysmal nocturnal haemoglobinuria. Eur J Haematol. 2025;115(2):125-133. doi:10.1111/ejh.14422
34. Zozula N, Slesicka I, Przestrzelska M, et al. The effect of physical activity on anxiety symptoms in adults: a literature review. Pedagogy and Psychology of Sport. 2026;12(1). Available at: https://apcz.umk.pl/PPS/article/view/69922
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Emil Pałyga, Mateusz Kwiatkowski, Zofia Leżańska, Katarzyna Marcinkowska, Aleksandra Cieślak, Sara Demkow, Karolina Siemińska, Joanna Sowińska, Natalia Paluszkiewicz, Sandra Bryg
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 72
Number of citations: 0
